{
  "symbol": "GMAB",
  "company_name": "Genmab A/S ADR",
  "ir_website": "https://www.genmab.com/investor-relations",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023",
          "url": "https://ir.genmab.com/genmab-news/new-releases/genmab-announces-net-sales-of-darzalex-daratumumab-for-third-quarter-of-2023",
          "content": "[Skip to content](#lfg-main-content)\n\n#  Page Not Found \n\n# Page Not Found\n\nWe are sorry, the page you requested cannot be found. Please check the URL or visit our [Homepage](/).\n\nYou are now leaving Genmab.com to go to our collaborator’s website.\n\nIf you continue, we encourage you to read the website’s privacy and cookie policy.\n\n[Continue](#) Cancel\n"
        },
        {
          "title": "Grant of Restricted Stock Units and Warrants to Employees in Genmab",
          "url": "https://ir.genmab.com/genmab-news/new-releases/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab",
          "content": "[Skip to content](#lfg-main-content)\n\n#  Page Not Found \n\n# Page Not Found\n\nWe are sorry, the page you requested cannot be found. Please check the URL or visit our [Homepage](/).\n\nYou are now leaving Genmab.com to go to our collaborator’s website.\n\nIf you continue, we encourage you to read the website’s privacy and cookie policy.\n\n[Continue](#) Cancel\n"
        },
        {
          "title": "Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)",
          "url": "https://ir.genmab.com/genmab-news/new-releases/genmab-announces-european-commission-approval-of-tepkinly-epcoritamab-for-adults-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl",
          "content": "[Skip to content](#lfg-main-content)\n\n#  Page Not Found \n\n# Page Not Found\n\nWe are sorry, the page you requested cannot be found. Please check the URL or visit our [Homepage](/).\n\nYou are now leaving Genmab.com to go to our collaborator’s website.\n\nIf you continue, we encourage you to read the website’s privacy and cookie policy.\n\n[Continue](#) Cancel\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Annual Report",
          "url": "https://www.genmab.com/investor-relations/annual-report",
          "content": "Global\n\n[](/)![Genmab Logo](/sfsites/c/cms/delivery/media/MC5MJ7XDOXGZD33FQOFIPPKUKT3M?version=2.1&channelId=0apMb00000000kn)\n\nsearch icon\n\n[![](/sfsites/c/cms/delivery/media/MC5MJ7XDOXGZD33FQOFIPPKUKT3M?version=2.1&channelId=0apMb00000000kn)](/)\n\nsearch icon\n\n**Genmab Regional Sites**\n\n“ \n\nCLOSE\n\nPause Video\n\n### Read the Chairman’s statement\n\nKey Stats\n\nOperating Profit*\n\nXXX,XXXXXXX\n\nSupporting Info comes here\n\n400 **2020**\n\n300 **2021**\n\n200 **2022**\n\n100 **2023**\n\nSupporting Copy Comes here\n\nLiquidity and Capital Resources\n\n[View all downloads](https://ir.genmab.com/download-library#content)\n\nExplore further\n\neyJuYW1lIjoiQW5udWFsX1JlcG9ydF9fYyJ9Annual Report Annual Report\n"
        },
        {
          "title": "2023 Letter To Shareholders | Genmab",
          "url": "https://www.genmab.com/news-insights/stories/2023-letter-to-shareholders-genmab",
          "content": "Global\n\n[](/)\n\nsearch icon\n\n[](/)\n\nsearch icon\n\n**Genmab Regional Sites**\n\neyJuYW1lIjoiWDIwMjNfbGV0dGVyX3RvX3NoYXJlaG9sZGVyc19nZW5tYWJfX2MifQ==2023 Letter To Shareholders | Genmab 2023 Letter To Shareholders | Genmab\n"
        }
      ]
    },
    {
      "section_name": "Media Library",
      "links": [
        {
          "title": "Key Documents",
          "url": "https://ir.genmab.com/download-library#content",
          "content": "[Skip to content](#lfg-main-content)\n\nResources\n\n#  Download Library \n\n  * [English](/download-library)\n  * [Danish](/da/download-library)\n\n\n\nCategories AllAnnual General MeetingAnnual ReportsArticles of associationCorporate Governance*Corporate PresentationsFact SheetInterim ReportsPodcastsWebcasts\n\nYear All2024202320222021202020192018201720162015201420132012201120102009200820072006200520042003200220012000\n\nArticles of association dated November 21, 2024 – English\n\n[ Download ](/static-files/30be9c19-2f54-427e-9152-56993bc6b3e4)\n\nInvestor Fact Sheet\n\n[ Download ](/static-files/4c3d4717-0fad-4b82-a7e4-e30f59bed25c)\n\nGeneral Terms and Conditions of Purchase\n\n[ Download ](/static-files/e1f428da-58c9-45f5-bcfc-53a9d6c80e99)\n\nGenmab First Nine Months 2024 Financial Results Presentation\n\n[ Download ](/static-files/3d0d1d5d-a02a-4a29-acbd-75eeadd68d53)\n\nGenmab Investor Presentation - November 2024\n\n[ Download ](/static-files/9cf9b1fd-ac9d-46ea-9834-0730621bc7be)\n\nInterim Report for the First Nine Months of 2024\n\n[ Download ](/static-files/9babf34b-bff3-40c7-a14c-29214f4f393a)\n\nGenmab First Half 2024 Financial Results Presentation\n\n[ Download ](/static-files/dfadfd4a-dd35-4040-93ae-18ba60dccd45)\n\nInterim Report for the First Half of 2024\n\n[ Download ](/static-files/3af714ca-2035-41b1-a889-2aa9b696a454)\n\nGenmab's Virtual mid- to late-stage pipeline update at ASCO 2024\n\n[ Download ](/static-files/47965121-a026-4b85-bed1-ade92f75961b)\n\nInterim Report for the First Quarter of 2024\n\n[ Download ](/static-files/e2d73d22-6921-44b5-899d-16fe466cf4b3)\n\nGenmab Q1 2024 Financial Results Presentation\n\n[ Download ](/static-files/e44dd5d1-e339-4761-81e3-8291d23e7fa0)\n\nVoting Results of the Annual General Meeting 2024\n\n[ Download ](/static-files/32a2ceaa-cae5-4369-997c-35dff077a2ba)\n\nProfoundBio Acquisition\n\n[ Download ](/static-files/d0b52ec8-bdc4-4358-a214-10a0fecae1ab)\n\nAGM 2024 Presentation\n\n[ Download ](/static-files/40496e24-7d16-485f-8aa8-631df8fc4925)\n\nGenmab 2023 Annual Report\n\n[ Download ](/static-files/1ce652aa-d110-408c-b4df-e37b32b787fe)\n\nCorporate Governance Report 2023 - English\n\n[ Download ](/static-files/0a157b7f-3a7f-4310-bc16-e7e78efd8dc7)\n\nGenmab 2023 Full Year Financial Results Presentation\n\n[ Download ](/static-files/662eb0b9-56b8-4700-9813-ac7e49e8b39c)\n\nBoard Diversity Matrix\n\n[ Download ](/static-files/f380d701-687c-47c4-9c7c-723bf44cf798)\n\nCorporate Responsibility Report 2023\n\n[ Download ](/static-files/c0341966-2b12-4013-ad8b-e21aeb167f1c)\n\nGenmab 2024 JP Morgan Presentation\n\n[ Download ](/static-files/1ff6369a-f66b-4fe0-8ecb-a308d133638d)\n\nGenmab R&D Update and ASH Data Review - December 2023\n\n[ Download ](/static-files/98a4c07a-c292-41bd-86ab-fce2963328ce)\n\nClinical Trial Transparency Declaration\n\n[ Download ](/static-files/adb5441f-4335-43cf-a988-19b919ee6869)\n\nGenmab First Nine Months 2023 Financial Results Presentation\n\n[ Download ](/static-files/8e08b836-4679-47cf-b9c3-0514659e2f1d)\n\nInterim Report for the First Nine Months of 2023\n\n[ Download ](/static-files/835ff23e-32c4-4bf5-82a3-020c16aaa614)\n\nInterim Report for the First Half of 2023\n\n[ Download ](/static-files/2142b519-2d66-4ec5-a0dc-8d525243d39b)\n\nGenmab First Half 2023 Financial Results Presentation\n\n[ Download ](/static-files/275fa5b7-410c-4ba4-a181-10c7cbd67ee3)\n\nYou are now leaving Genmab.com to go to our collaborator’s website.\n\nIf you continue, we encourage you to read the website’s privacy and cookie policy.\n\n[Continue](#) Cancel\n"
        }
      ]
    }
  ]
}